Protara Therapeutics, Inc. (TARA )
Currency in USD Disclaimer
Subscribe Now for Delta3 AI Alerts
Don’t miss out on top stock picks and market insights. Subscribe to Delta3 AI Alerts for real-time updates and expert analysis straight to your inbox. Stay informed and maximize your investment potential.
Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
- Symbol TARA
- Company Protara Therapeutics, Inc.
- Price $5.69
- Changes Percentage -23.38
- Change -1.74
- Day Low $5.59
- Day High $6.33
- Year High $7.82
- Year Low $2.77
- Market Cap $219,669,567
- Price Avg 50 EMA (D) $5.95
- Price Avg 200 EMA (D) $4.47
- Exchange NASDAQ
- Volume 4,228,149
- Average Volume 986,573
- Open $6.26
- Previous Close $7.43
- EPS -1.39
- PE -4.10
- Earnings Announcement 2026-03-05 13:30:00
- Shares Outstanding $38,589,296
Company brief: PROTARA THERAPEUTICS, INC. (TARA )
- Healthcare
- Biotechnology
- Mr. Jesse Shefferman
- https://www.protaratx.com
- US
- N/A
- 10-22-2014
- US74365U1079
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease. The company was formerly known as ArTara Therapeutics, Inc. and changed its name to Protara Therapeutics, Inc. in May 2020. Protara Therapeutics, Inc. is headquartered in New York, New York.